Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
• To assess the safety and tolerability of CDZ173 in patients with primary Sjögren’s syndrome. • To compare the effect of CDZ173 versus placebo on the patient-reported outcomes of primary Sjögren’s syndrome patients after 12 weeks of treatment (study week 13).
Inclusion criteria
- Primary Sjögren’s syndrome